TROPHIMMUN Trial Finds Avelumab Effective in Rare Gynecologic Tumor Resistant to Chemotherapy
The first trial of immunotherapy for gestational trophoblastic tumors proved effective in almost 50% of patients resistant to single-agent...
Patients With Cancer—Especially Progressive Disease—Infected With COVID-19 May Have an Increased Risk of Death
A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause...
Tucatinib Combination in Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases
In an analysis of the pivotal phase III HER2CLIMB trial reported at the ASCO20 Virtual Scientific Program, Nancy U. Lin, MD...
Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Howard A. ‘Skip’ Burris III: United Against Cancer to Accelerate Progress for Patients
Fred Hirsch and Colleagues: How the Lung Cancer Community Came Together During the COVID-19 Pandemic
Mohammad Khan and Clayton Hess: On the Shoulders of Giants
Luis E. Pino V: 10 Changes I Will Make in My Oncology Practice as a Result of COVID-19
Philip Salem: What Have I Learned in More Than Half a Century in Cancer Medicine?
Sponsored Content
Sponsored By AstraZeneca
PARP Inhibitors: Changing the Treatment Paradigm in Ovarian Cancer
Sponsored by QED Therapeutics
Novel Therapies Targeting FGFR-Altered Advanced Cholangiocarcinoma
Ivosidenib for IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma
As reported by Ghassan K. Abou-Alfa, MD, and colleagues in The Lancet Oncology, the phase III ClarIDHy trial has shown that the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib improved progression-free survival vs placebo in patients with advanced IDH1-mutant chemotherapy-refractory...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Patients With Cancer—Especially Progressive Disease—Infected With COVID-19 May Have an Increased Risk of Death
A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe...
Patients With Cancer—Especially Progressive Disease—Infected With COVID-19 May Have an Increased Risk of Death
A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Is Sentinel Lymph Node Biopsy Alone Oncologically Safe for Patients With Early-Stage Cervical Cancer?
In a study of patients with early-stage cervical cancer presented by Balaya et al during the Gynecologic Cancer Oral Abstract Session of the ASCO20 Virtual Scientific Program (Abstract 6006), researchers assessed disease-free and disease-specific survival to determine whether sentinel lymph node...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
Metastatic Urothelial Cancer: A Conversation on State-of-the-Art Treatment Before the ASCO20 Virtual Scientific Program
Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Results From the ACTS-CC 02 Trial on Adjuvant Chemotherapy
Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture
Rowan T. Chlebowski, MD, PhD, on Diet and Breast Cancer: Trial Results
